Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to insufficient growth and late pubertal development in cases of disease onset during childhood or adolescence. During the last decade, the role of anti-tumor necrosis factor (TNF) in the treatment of paediatric-onset IBD has gained more ground. The number of biologicals presently available for children and adolescents with IBD has increased, biosimilars have become available, and practices in adult gastroenterology with regards to anti-TNF have changed. The aim of this study is to review the current evidence on the indications, judicious use, effectiveness and safety of anti-TNF agents in paediatric IBD. A PubMed literature search was performed and included articles published after 2000 using the following terms: child or paediatric, Crohn, ulcerative colitis, inflammatory bowel disease, anti-TNF, TNF alpha inhibitor, infliximab, adalimumab, golimumab and biological. Anti-TNF agents, specifically infliximab and adalimumab, have proven to be effective in moderate and severe paediatric IBD. Therapeutic drug monitoring increases therapy effectiveness and safety. Clinical predictors for anti-TNF response are currently of limited value because of the variation in outcome definitions and follow-ups. Future research should comprise large cohorts and clinical trials comparing groups according to their risk profile in order to provide personalized therapeutic strategies.

Additional Metadata
Keywords anti-TNF, biological, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, paediatrics, children, adolescents
Persistent URL dx.doi.org/10.3390/ijms20102529, hdl.handle.net/1765/117703
Journal International journal of molecular sciences
Citation
Aardoom, M.A., Veereman, G, & de Ridder, L. (2019). A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. International journal of molecular sciences, 20(10). doi:10.3390/ijms20102529